Trial to investigate if statins could become multiple sclerosis treatment – Medical Xpress

May 9, 2017

A UCL researcher is leading a phase 3 trial involving more than 1,000 people with multiple sclerosis (MS) to investigate whether simvastatin could become a treatment for the condition.

The project will cost almost 6 million and is being funded by collaboration between the National Institute for Health Research (NIHR), the MS Society (UK), the National MS Society (US), the NHS and UK universities.

The trial will test simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. There are currently no licensed treatments that can slow or stop disability progression in people with this type of MS.

The research will be led by Dr Jeremy Chataway (UCL Institute of Neurology), who led the phase 2 trial into simvastatin that was published in The Lancet in 2014. It involved 140 people with secondary progressive MS. The research found those taking high doses of the drug had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of study.

Dr Chataway said: "This drug holds incredible promise for the thousands of people living with secondary progressive MS in the UK, and around the world, who currently have few options for treatments that have an effect on disability. This study will establish definitively whether simvastatin is able to slow the rate of disability progression over a three year period, and we are very hopeful it will."

The video will load shortly

Michelle Mitchell, Chief Executive of the MS Society, said: "We're incredibly proud to be co-funding the simvastatin trial. This is a momentous step forward in our quest to find an effective treatment for progressive MS. More than 100,000 people in the UK are living with MS and this research will offer a huge amount of hope to the majority of them."

MS attacks the nervous system, it's often painful and exhausting and can cause problems with how we walk, move, see, think and feel. The condition is unpredictable and different for everyone.

Stuart Nixon, who lives with secondary progressive MS, said: "At the moment people like me are living with the prospect of our condition getting worse each day. This is the most exciting opportunity to change how we manage progressive MS. It would be amazing if this trial can show that an existing drug, costing just a few pence a day, can help with MS."

The simvastatin trial will involve 1180 people with secondary progressive MS at almost thirty centres across the UK. It will take six years to complete, with the first people receiving medication later this year.

Explore further: Statins slow the progression of advanced multiple sclerosis in clinical trial

Statins may provide doctors with an unlikely new weapon with which to slow the progression of multiple sclerosis (MS).

A clinical trial using cholesterol-lowering treatment Simvastatin in people living with Parkinson's is getting underway in centres across the countrywith the hope that it could become one of a number of effective treatments ...

French biotechnology company MedDay on Friday announced encouraging results for a multiple sclerosis (MS) drug trial, saying it decreased its progress and in some cases led to a "significant improvement" for sufferers.

Neurologist Dr. Matthew Tremblay, who specializes in the care of patients with multiple sclerosis at UConn Health, discusses the first drug just approved by the FDA for patients with difficult to treat primary progressive ...

(HealthDay)Lipid-lowering therapy with ezetimibe plus simvastatin is associated with improved clinical outcomes, with a reduction in total primary end point (PEP) events, according to a study published in the Feb. 2 issue ...

(HealthDay)For patients stabilized after acute coronary syndrome (ACS), a nine-point risk stratification tool can identify patients who will derive benefit from the addition of ezetimibe to statin therapy, according to ...

Harvard scientists are beginning to provide answers to one of the thorniest questions in psychology: How do we think?

A region of the brain that helps to manage body functions including stress, heart rate and blood pressure reacts differently between men and women when presented with certain stimuli, according to a new study from the UCLA ...

Robert Bush has multiple sclerosis (MS), which sapped his ability to walk five years ago. Joseph McGlynn suffered a stroke that seriously impaired his left side, also five years ago.

Studies have shown that loss of the sense of smell can be among the first warning signs of diseases such as Alzheimer's and Parkinson's. Now a researcher at the Perelman School of Medicine at the University of Pennsylvania ...

Memory performance decreases with increasing age. Cannabis can reverse these ageing processes in the brain. This was shown in mice by scientists at the University of Bonn with their colleagues at The Hebrew University of ...

(Medical Xpress)The human brain's capacity for learning is adaptable to a variety of conditions. When the environment changes repeatedly and constantly, learning is difficult, because the brain automatically seeks patterns ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:
Trial to investigate if statins could become multiple sclerosis treatment - Medical Xpress